EA201600331A1 - PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLUTION FOR INTRAVENOUS AND INTRAINAL INTRODUCTION AND METHOD FOR ITS PREPARATION - Google Patents
PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLUTION FOR INTRAVENOUS AND INTRAINAL INTRODUCTION AND METHOD FOR ITS PREPARATIONInfo
- Publication number
- EA201600331A1 EA201600331A1 EA201600331A EA201600331A EA201600331A1 EA 201600331 A1 EA201600331 A1 EA 201600331A1 EA 201600331 A EA201600331 A EA 201600331A EA 201600331 A EA201600331 A EA 201600331A EA 201600331 A1 EA201600331 A1 EA 201600331A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- intravenous
- solution
- pharmaceutical composition
- intrainal
- introduction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к области медицины и химико-фармацевтической промышленности, а именно к лекарственному средству в форме раствора для инъекций для лечения заболеваний головного мозга и способу получения этого лекарственного средства. Заявлен состав фармацевтической композиции в форме раствора для внутривенного и внутримышечного введения, содержащий в качестве активного ингредиента 6-метил-2-этилпиридин-3-ол соль (2S)-2-ацетаминопентандиовой кислоты, а также способ получения указанной композиции. Заявленная группа изобретений позволяет впервые получить готовую лекарственную форму на основе 6-метил-2-этилпиридин-3-ол соль (2S)-2-ацетаминопентандиовой кислоты.The invention relates to the field of medicine and the pharmaceutical industry, namely to the drug in the form of an injection for the treatment of diseases of the brain and the method of obtaining this drug. The claimed composition of the pharmaceutical composition in the form of a solution for intravenous and intramuscular administration, containing as active ingredient 6-methyl-2-ethylpyridin-3-ol salt (2S) -2-acetaminopentanedioic acid, as well as a method of obtaining this composition. The claimed group of inventions allows for the first time to obtain a finished dosage form based on 6-methyl-2-ethylpyridin-3-ol salt of (2S) -2-acetaminopentanedioic acid.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015108664A RU2637168C2 (en) | 2015-03-12 | 2015-03-12 | Pharmaceutical composition in form of solute for intravenous and intramuscular injection and its production process |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201600331A1 true EA201600331A1 (en) | 2016-10-31 |
EA034722B1 EA034722B1 (en) | 2020-03-12 |
Family
ID=53433611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201600331A EA034722B1 (en) | 2015-03-12 | 2016-02-25 | Pharmaceutical composition in the form of intravenous and intramuscular solution and method of production thereof |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA034722B1 (en) |
RU (1) | RU2637168C2 (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2284993C2 (en) * | 2002-06-14 | 2006-10-10 | Леонид Дмитриевич Смирнов | 2-ethyl-6-methyl-3-oxypyrodine salts with organic carboxylic acids possessing anxiolytic, antidepressive, antihypoxic, anti-amnestic and anti-oxidative activity and method for their preparing |
RU2357955C2 (en) * | 2006-04-21 | 2009-06-10 | Смирнова Лариса Каземировна | Antioxidant, antihyperglycemic, hypolipidemic and antishock n-acetylcysteinate 2-ethyl-6-methyl-3-hydroxypyridine |
RU2380089C2 (en) * | 2008-04-04 | 2010-01-27 | Закрытое Акционерное Общество "Фармфирма "Сотекс" | Pharmaceutical composition for injections |
RU2504376C1 (en) * | 2012-05-04 | 2014-01-20 | Галина Викторовна Сукоян | High-stable pharmaceutical formulation of lyophilisate of 3-oxypyridine and methylpyridine derivatives and pharmaceutically acceptable salts thereof |
RU2493841C1 (en) * | 2012-10-09 | 2013-09-27 | Станислав Анатольевич Кедик | Synergetic preparation for treating cardiovascular diseases, diabetes mellitus and hepatobiliary diseases |
-
2015
- 2015-03-12 RU RU2015108664A patent/RU2637168C2/en active
-
2016
- 2016-02-25 EA EA201600331A patent/EA034722B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2015108664A (en) | 2015-06-20 |
EA034722B1 (en) | 2020-03-12 |
RU2637168C2 (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118826T1 (en) | PROCEDURE FOR CONSTRUCTION OF A GLATIRAMER ACETATE CONTAINER | |
EA202090573A1 (en) | COMPOSITIONS OF NIRAPARIBA | |
NI201100194A (en) | DERIVATIVES OF HAVE [2, 3 - B] PYRIDINE AS INHIBITORS OF VIRAL REPLICATION | |
NZ631100A (en) | Soft chewable pharmaceutical products | |
EA201791727A1 (en) | 7-BENZYL-4- (2-METHYLBENZIL) -2,4,6,7,8,9-HEXAHYDROIMIDAZO [1,2-A] PYRIDO [3,4-E] PYRIMIDIN-5 (1H) -OH, ITS ANALOGUES AND SALTS AND METHODS OF THEIR APPLICATION IN THERAPY | |
EA201590697A1 (en) | DERIVATIVES OF KETAMINE | |
EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
EA201590797A1 (en) | PREPARATIONS WITH THE MODIFIED PROBE RELEASE | |
EA201501054A1 (en) | TREATMENT OF MYOPATHIES AND NEURODEGENERATIVE DISEASES ASSOCIATED WITH THE PROTECTION OF PROTEINS BY PARENTAL INTRODUCTION OF TRAGOSE | |
CY1122899T1 (en) | AQUEOUS FORMULATION INCLUDING PARACETAMOL AND IBUPROPHEN | |
EA201491427A1 (en) | SUBSTITUTED PHENYLIMIDAZOPIRAZOLES AND THEIR APPLICATION | |
EA201690183A1 (en) | SUBSTITUTED PYRAZOLOPIRIDINAMINES | |
FI3383385T4 (en) | Melflufen dosage regimens for cancer | |
EA201691693A3 (en) | COMBINED MEDICINE PREPARATION IN THE FORM OF SPELLING TABLETS AND METHOD OF ITS PREPARATION | |
EA201990550A1 (en) | OPHTHALMIC DRUG INCLUDING THE ASOLIC COMPOUND | |
EA201600331A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLUTION FOR INTRAVENOUS AND INTRAINAL INTRODUCTION AND METHOD FOR ITS PREPARATION | |
BR112018008769A2 (en) | pharmaceutical formulations, reconstituted and lyophilized aqueous liquid formulations, syringe, method of manufacturing a pharmaceutical formulation, method for treating a disease and use of a reconstructed formulation | |
EA201391512A1 (en) | SOLID PHARMACEUTICAL COMPOSITION | |
EA201790140A1 (en) | PHARMACEUTICAL MEDICINE FORMS | |
EA201600332A3 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS COVERED WITH THE INTESTINAL SOLUTION SHELL, AND THE METHOD OF ITS OBTAINING | |
EA201992816A1 (en) | PHARMACEUTICAL COMPOSITION AND MEDICINAL FORM THAT INCLUDES (E) -4- (2- (AMINOMETHYL) -3-FLOROLLYLOXY) -N-THR-BUTYLBENZAMIDE, METHOD FOR THEIR PREPARATION AND APPLICATION, APPLICATION | |
EA201491477A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUPIRTIN | |
UA117389C2 (en) | MEDICINAL PRODUCT IN THE FORM OF CONCENTRATE FOR PREPARATION OF THE INFUSION SOLUTION | |
EA201600336A3 (en) | MEDICINE FOR PREVENTION AND TREATMENT OF BRAIN DISEASES AND METHOD FOR TREATING BRAIN DISEASES | |
WO2016115442A3 (en) | Therapeutic protein formulations |